Recent Advances in Nuclear Forensic Chemistry.

Anal Chem

Los Alamos National Laboratory, Chemistry Division, Mailstop J-514, Los Alamos, New Mexico 87545, United States.

Published: January 2021

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.analchem.0c03571DOI Listing

Publication Analysis

Top Keywords

advances nuclear
4
nuclear forensic
4
forensic chemistry
4
advances
1
forensic
1
chemistry
1

Similar Publications

A review of state-of-the-art resolution improvement techniques in SPECT imaging.

EJNMMI Phys

January 2025

Department of Nuclear Medicine, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, 230001, Anhui, China.

Single photon emission computed tomography (SPECT), a technique capable of capturing functional and molecular information, has been widely adopted in theranostics applications across various fields, including cardiology, neurology, and oncology. The spatial resolution of SPECT imaging is relatively poor, which poses a significant limitation, especially the visualization of small lesions. The main factors affecting the limited spatial resolution of SPECT include projection sampling techniques, hardware and software.

View Article and Find Full Text PDF

Purpose: The common approach for organ segmentation in hybrid imaging relies on coregistered CT (CTAC) images. This method, however, presents several limitations in real clinical workflows where mismatch between PET and CT images are very common. Moreover, low-dose CTAC images have poor quality, thus challenging the segmentation task.

View Article and Find Full Text PDF

A Framework for Assessing Viral Pathogens: A Key Element of the BARDA Emerging Infectious Diseases Strategy.

Health Secur

January 2025

Richard C. White, PhD, is an Interdisciplinary Scientist, Medical Countermeasures Program; Peter L. Adams, PhD, and Karl J. Erlandson, PhD, are Interdisciplinary Scientists, and Ramya Natarajan, PhD, is a Health Scientist, Influenza and Emerging Infectious Diseases Division; Kyla A. Britson, PhD, Rushyannah Killens-Cade, PhD, and Malen A. Link, PhD, are Interdisciplinary Scientists, and Daniel N. Wolfe, PhD, is Deputy Director, Division of Chemical, Biological, Radiological, and Nuclear (CBRN) Countermeasures; Derek L. Eisnor, MD, is a Medical Officer, Division of Clinical Development; Brenda L. Fredericksen, PhD, is Program Director, Nonclinical Research Program, and James Little, MS, is a Senior Scientific Advisor, Division of Nonclinical Development; John S. Lee, PhD, is Program Director, Molecular Diagnostics Program, and Julie M. Villanueva, PhD, is a Scientific Advisor, Detection, Diagnostics, and Devices Infrastructure Division; Kimberly L. Sciarretta, PhD, is Program Director, Launch Office, Division of Research, Innovation, and Ventures; and Robert A. Johnson, PhD, is Director, Medical Countermeasures Program; all at the Biomedical Advanced Research and Development Authority, Washington, DC. Gerald R. Kovacs, PhD, is a Senior Advisor; Huyen Cao, MD, is a Senior Clinical Studies Analyst; Christopher Dale, PhD, and Mark Michalik, MBA, are Senior Subject Matter Experts; Mario H. Skiadopoulos, PhD, is a Preclinical Drug Development Subject Matter Expert; and Xiaomi Tong, PhD, is a Senior Regulatory Affairs Subject Matter Expert; all at Tunnell Government Services, Berwyn, PA. Suchismita Chandran, PhD, is a Lead Associate, and Michael Rowe, MS, is a Senior Consultant; both at Booz Allen Hamilton, McLean, VA. Ethan J. Fritch, PhD, is an ORISE Fellow, Oak Ridge Institute for Science and Education, Oak Ridge, TN. George Robertson, PhD, is Chief Scientific Officer, Cambra Consulting, Inc., Woodbridge, VA.

The COVID-19 pandemic has revealed the need for nations to prepare more effectively for emerging infectious diseases. Preparing for these threats requires a multifaceted approach that includes assessing pathogen threat, building flexible capabilities for rapid medical countermeasure (MCM) development, and exercising, maintaining, and improving those response capabilities. The Biomedical Advanced Research and Development Authority (BARDA) promotes the advanced development of MCMs in response to natural and manmade threats.

View Article and Find Full Text PDF

Methane (CH), which is the main component of natural gas, is an abundant and widely available carbon resource. However, CH has a low energy density of only 36 kJ L under ambient conditions, which is significantly lower than that of gasoline (. 34 MJ L).

View Article and Find Full Text PDF

Zircaloy-4 (Zr-4) is widely used as the cladding material in nuclear power plants (NPPs) due to its excellent corrosion resistance and low neutron absorption cross-section. Under Loss of Coolant Accident (LOCA) conditions, oxidation of Zr-4 can compromise the safety of the NPPs by accelerating hydrogen production. Therefore, enhancing the oxidation resistance of Zr-4 is a critical research focus.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!